Payment overview · 2025
General Payments
$240.43
13 reported records · 7 companies
Healthcare provider profile · identity verified
Irene Buckner, M.D.
Allopathic & Osteopathic Physicians|General Practice · CLARKSDALE, MS · NPI 1003836669
Verified facts
What the public records show
CMS Open Payments records show Irene Buckner, M.D. received $240.43 in general payments during 2025 across 13 reported records.
Exact Sciences Corporation accounted for 26.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuedexta, Ozempic, Rybelsus.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nuedexta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $62.59 | 26.0% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.52 | 18.1% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $39.63 | 16.5% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $37.71 | 15.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.53 | 8.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.33 | 8.5% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.12 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $240.43 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $62.59 | 4 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $43.52 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $39.63 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $37.71 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.53 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Tresiba Normalized: tresiba |
Drug | Novo Nordisk Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUEDEXTA nuedexta |
2025 | Nuedexta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 97 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 62 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
74 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
97 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 452 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 369 | 74 |
| Potassium Chloride | Potassium Chloride | 300 | 43 |
| Risperidone | Risperidone | 298 | 26 |
| Levetiracetam | Levetiracetam | 295 | 30 |
| Montelukast Sodium | Montelukast Sodium | 279 | 44 |
| Gabapentin | Gabapentin | 264 | 63 |
| Quetiapine Fumarate | Quetiapine Fumarate | 222 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 217 | 41 |
| Carvedilol | Carvedilol | 207 | 48 |
| Olanzapine | Olanzapine | 202 | 14 |
| Oxcarbazepine | Oxcarbazepine | 198 | 16 |
| Benztropine Mesylate | Benztropine Mesylate | 195 | 16 |
| Levothyroxine Sodium | Levothyroxine Sodium | 194 | 24 |
| Divalproex Sodium Er | Divalproex Sodium | 185 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 183 | 56 |
| Losartan Potassium | Losartan Potassium | 175 | 36 |
| Januvia | Sitagliptin Phosphate | 156 | 17 |
| Metformin Hcl | Metformin Hcl | 155 | 24 |
| Sertraline Hcl | Sertraline Hcl | 152 | 18 |
| Xarelto | Rivaroxaban | 152 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 146 | 13 |
| Haloperidol | Haloperidol | 146 | 11 |
| Linzess | Linaclotide | 144 | 25 |
| Divalproex Sodium | Divalproex Sodium | 143 | 14 |
| Lamotrigine | Lamotrigine | 142 | 14 |
| Eliquis | Apixaban | 140 | 13 |
| Enalapril Maleate | Enalapril Maleate | 140 | 18 |
| Trazodone Hcl | Trazodone Hcl | 135 | 17 |
| Furosemide | Furosemide | 132 | 20 |
| Metoprolol Succinate | Metoprolol Succinate | 132 | 23 |
| Scopolamine | Scopolamine | 124 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 119 | 29 |
| Famotidine | Famotidine | 117 | 16 |
| Metoprolol Tartrate | Metoprolol Tartrate | 117 | 16 |
| Simvastatin | Simvastatin | 112 | 17 |
| Buspirone Hcl | Buspirone Hcl | 106 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 25 |
| Meloxicam | Meloxicam | 99 | 44 |
| Ozempic | Semaglutide | 97 | 27 |
| Nifedipine Er | Nifedipine | 91 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 15 |
| Metoclopramide Hcl | Metoclopramide Hcl | 86 | 12 |
| Mirtazapine | Mirtazapine | 85 | 12 |
| Latanoprost | Latanoprost | 82 | 11 |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 14 |
| Clozapine | Clozapine | 80 | suppressed |
| Celecoxib | Celecoxib | 79 | 31 |
| Lactulose | Lactulose | 76 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 26 |
| Jardiance | Empagliflozin | 74 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 74 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 14 |
| Clonazepam | Clonazepam | 71 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 70 | suppressed |
| Spironolactone | Spironolactone | 69 | 13 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 67 | suppressed |
| Rybelsus | Semaglutide | 62 | 16 |
| Benazepril Hcl | Benazepril Hcl | 60 | 15 |
| Lisinopril | Lisinopril | 59 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 54 | 11 |
| Lacosamide | Lacosamide | 53 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 12 |
| Metformin Hcl Er | Metformin Hcl | 50 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 49 | 14 |
| Aripiprazole | Aripiprazole | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 49 | suppressed |
| Finasteride | Finasteride | 45 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 22 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 11 |
| Lithium Carbonate Er | Lithium Carbonate | 43 | suppressed |
| Memantine Hcl | Memantine Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 40 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 40 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 39 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Indapamide | Indapamide | 37 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 36 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 36 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Paliperidone Er | Paliperidone | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 33 | 16 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Pregabalin | Pregabalin | 32 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 16 |
| Albuterol Sulfate | Albuterol Sulfate | 30 | 16 |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 29 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 17 |
| Zonisamide | Zonisamide | 27 | suppressed |
| Cilostazol | Cilostazol | 26 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 25 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 12 |
| Propylthiouracil | Propylthiouracil | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 24 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 18 |
| Cinacalcet Hcl | Cinacalcet Hcl | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 16 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 16 |
| Theophylline Er | Theophylline Anhydrous | 23 | suppressed |
| Amantadine | Amantadine Hcl | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Valproic Acid | Valproic Acid | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | 16 |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Klor-Con 10 | Potassium Chloride | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Sulindac | Sulindac | 18 | 12 |
| Cephalexin | Cephalexin | 17 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Austedo | Deutetrabenazine | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 11 |
| Megestrol Acetate | Megestrol Acetate | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rytary | Carbidopa/Levodopa | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $240.43 · 13 records | Exact Sciences Corporation | Cologuard Collection Kit, IBSRELA, Leqembi, MOUNJARO, NUEDEXTA, Ozempic, Rybelsus, Tresiba, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuedexta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error